RT Journal Article
T1 CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation.
A1 Honda, Kazufumi
A1 Katzke, Verena A
A1 Hüsing, Anika
A1 Okaya, Shinobu
A1 Shoji, Hirokazu
A1 Onidani, Kaoru
A1 Olsen, Anja
A1 Tjønneland, Anne
A1 Overvad, Kim
A1 Weiderpass, Elisabete
A1 Vineis, Paolo
A1 Muller, David
A1 Tsilidis, Kostas
A1 Palli, Domenico
A1 Pala, Valeria
A1 Tumino, Rosario
A1 Naccarati, Alessio
A1 Panico, Salvatore
A1 Aleksandrova, Krasimira
A1 Boeing, Heiner
A1 Bueno-de-Mesquita, H Bas
A1 Peeters, Petra H
A1 Trichopoulou, Antonia
A1 Lagiou, Pagona
A1 Khaw, Kay-Tee
A1 Wareham, Nick
A1 Travis, Ruth C
A1 Merino, Susana
A1 Duell, Eric J
A1 Rodríguez-Barranco, Miguel
A1 Chirlaque, María Dolores
A1 Barricarte, Aurelio
A1 Rebours, Vinciane
A1 Boutron-Ruault, Marie-Chiristine
A1 Romana Mancini, Francesca
A1 Brennan, Paul
A1 Scelo, Ghislaine
A1 Manjer, Jonas
A1 Sund, Malin
A1 Öhlund, Daniel
A1 Canzian, Federico
A1 Kaaks, Rudolf
K1 CA19-9
K1 apolipoprotein A2
K1 early detection
K1 isoforms
K1 pancreatic cancer
K1 prospective study
AB Recently, we identified unique processing patterns of apolipoprotein A2 (ApoA2) in patients with pancreatic cancer. Our study provides a first prospective evaluation of an ApoA2 isoform ("ApoA2-ATQ/AT"), alone and in combination with carbohydrate antigen 19-9 (CA19-9), as an early detection biomarker for pancreatic cancer. We performed ELISA measurements of CA19-9 and ApoA2-ATQ/AT in 156 patients with pancreatic cancer and 217 matched controls within the European EPIC cohort, using plasma samples collected up to 60 months prior to diagnosis. The detection discrimination statistics were calculated for risk scores by strata of lag-time. For CA19-9, in univariate marker analyses, C-statistics to distinguish future pancreatic cancer patients from cancer-free individuals were 0.80 for plasma taken ≤6 months before diagnosis, and 0.71 for >6-18 months; for ApoA2-ATQ/AT, C-statistics were 0.62, and 0.65, respectively. Joint models based on ApoA2-ATQ/AT plus CA19-9 significantly improved discrimination within >6-18 months (C = 0.74 vs. 0.71 for CA19-9 alone, p = 0.022) and ≤ 18 months (C = 0.75 vs. 0.74, p = 0.022). At 98% specificity, and for lag times of ≤6, >6-18 or ≤ 18 months, sensitivities were 57%, 36% and 43% for CA19-9 combined with ApoA2-ATQ/AT, respectively, vs. 50%, 29% and 36% for CA19-9 alone. Compared to CA19-9 alone, the combination of CA19-9 and ApoA2-ATQ/AT may improve detection of pancreatic cancer up to 18 months prior to diagnosis under usual care, and may provide a useful first measure for pancreatic cancer detection prior to imaging.
YR 2018
FD 2018-12-04
LK http://hdl.handle.net/10668/13003
UL http://hdl.handle.net/10668/13003
LA en
DS RISalud
RD Apr 17, 2025